Skip to content
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-PID – AAV-NAbs Positive Patients
    • VTX–806 – Cerebrotendinous Xanthomatosis
    • VTX-802 & VTX-803 – PFIC
    • VTX-801 – Wilson’s disease
    • VTX-801 – GATEWAY Clinical Trial
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-PID – AAV-NAbs Positive Patients
    • VTX–806 – Cerebrotendinous Xanthomatosis
    • VTX-802 & VTX-803 – PFIC
    • VTX-801 – Wilson’s disease
    • VTX-801 – GATEWAY Clinical Trial
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet

Category: Events

VIVET ANNOUNCES 2 PRESENTATIONS ON ITS LEAD PRODUCT VTX-801 AT THE 2018 ASGCT ANNUAL MEETING

Vivet Therapeutics announces 2 presentations on its lead product

Vivet sponsoring and attending Wilson Disease Association (WDA) 2018 Annual Conference

Vivet Therapeutics’ CEO, Jean-Philippe Combal

Vivet announces presentation on its lead product at the upcoming 2018 International Liver Congress

Vivet Therapeutics announces presentation on its lead product at the upcoming 

Vivet is sponsoring and attending the 9th Congress of the Spanish Society for Gene and Cell Therapy

Vivet is a gold sponsor of the

Vivet participating to a panel at 2018 Biotech & Money congress

ean-Philippe Combal, Vivet Therapeutics’ CEO

Vivet hosting meetings during JPM 2018 Healthcare Conference

Jean-Philippe Combal, Vivet Therapeutics’ CEO

Vivet attending Jefferies 2017 London Healthcare Conference

Jean-Philippe Combal, Vivet Therapeutics’ CEO, and Thomas Daniel, BD Director, will be hosting 1×1 meetings during Jefferies 2017 London Healthcare Conference on…

Vivet will be at BIO Europe in Berlin on November 6-8th

Vivet Therapeutics will be at BIO Europe in Berlin on November 6-8th 2017

Vivet presenting at Gene Therapy for Rare Disorders Europe

Vivet Therapeutics will be presenting at Gene Therapy for Rare Disorders Europe on Oct 31-Nov 2, 2017

Vivet will be at AASLD Liver Meeting 2017

Vivet Therapeutics will be at

← Previous
Next →
Twitter Linkedin
About us
  • Our DNA
  • Board members
  • Our team
  • Partners
  • Our DNA
  • Board members
  • Our team
  • Partners
Pipeline
  • VTX-PID – AAV-NAbs Positive Patients
  • VTX – 806 – Cerebrotendinous Xanthomatosis
  • VTX-802 & VTX-803 – PFIC
  • VTX-801 – Wilson’s disease
  • VTX-801 – GATEWAY Clinical Trial
  • VTX-PID – AAV-NAbs Positive Patients
  • VTX – 806 – Cerebrotendinous Xanthomatosis
  • VTX-802 & VTX-803 – PFIC
  • VTX-801 – Wilson’s disease
  • VTX-801 – GATEWAY Clinical Trial
Patients & Families
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact

Vivet Therapeutics Cookie Policy

Vivet Therapeutics Privacy Policy

Vivet Therapeutics
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}